Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tumor-immunology jargon, trial readouts, and frequent capital raises make Purple Biotech’s SEC disclosures dense. A single Purple Biotech annual report 10-K simplified still runs hundreds of pages, while each Purple Biotech 8-K material events explained can shift sentiment overnight. If you’ve ever asked “Where can I find Purple Biotech quarterly earnings report 10-Q filing?” or searched for “Purple Biotech insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI turns that challenge into clarity. Our platform streams every Purple Biotech SEC filings explained simply the moment they hit EDGAR and delivers AI-powered summaries that translate oncology science and financial footnotes into plain English. Whether you need Purple Biotech Form 4 insider transactions real-time, a Purple Biotech proxy statement executive compensation breakdown, or a quick Purple Biotech earnings report filing analysis, the information appears in seconds. Interactive dashboards connect text, tables, and exhibits, helping you understand Purple Biotech SEC documents with AI rather than hours of scrolling.
Because PPBT is a clinical-stage biotech, filings often reveal cash runway, trial milestones, collaboration terms, and Purple Biotech executive stock transactions Form 4—details that drive valuation long before revenue. Investors track 10-Q R&D spend to gauge burn, monitor 8-K headlines for trial updates, and watch for insider buys that may signal confidence. With comprehensive coverage, real-time alerts, and expert commentary, Stock Titan equips you to follow every Purple Biotech disclosure and make informed decisions faster.
Purple Biotech Ltd. received a Schedule 13G filing from Orca Capital AG reporting beneficial ownership of 605,000 ADSs, representing 9.9% of the outstanding American Depositary Shares (based on 6,085,450 ADSs outstanding after the issuer's registered offering). Orca Capital states sole voting and dispositive power over these ADSs and files as a German reporting person. The filing notes that the Reporting Person holds additional pre-funded and Series B warrants that are subject to a 4.99% blocker, preventing exercise that would increase beneficial ownership above 4.99% of ordinary shares under the warrants' terms. The filing is certified by Thomas Konig, Director of Orca Capital AG.
Purple Biotech Ltd. is offering 3,055,000 ADSs (representing 611,000,000 Ordinary Shares) together with 6,110,000 Warrants to purchase up to 6,110,000 ADSs. The placement agent fee is 7.0% of gross proceeds, shown as $419,999.93, leaving estimated proceeds to the company of $5,579,704.57 before other offering expenses. The company estimates additional offering expenses (excluding placement agent fees) of approximately $215,000. Proceeds are intended to fund oncology therapeutic development and general corporate purposes. The prospectus discloses multiple historic and outstanding equity instruments and warrants with specified exercise prices and ADS equivalents, and states Ordinary Shares outstanding after this offering would be 1,806,089,801 assuming full exercise of the Pre-Funded Warrants and no exercise of the offered Warrants. The ADSs trade on Nasdaq under the symbol PPBT, and a 60-day director/officer lock-up applies. Clinical program details include NT219, with a Phase 2 investigator-initiated study initiated in June 2025.
Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.” The press release is included as Exhibit 99.1.
The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release—and all statements therein—into the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.
Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates “significant advantages” and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
